Corcept Therapeutics Hit With Securities Fraud Class Action Over Relacorilant Claims

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Corcept Therapeutics Incorporated ($CORT), alleging that the biopharmaceutical company made materially false and misleading statements regarding its flagship drug candidate relacorilant and its regulatory approval prospects. The complaint centers on claims that Corcept misrepresented the strength of clinical trial data while concealing FDA concerns about insufficient clinical evidence supporting the drug's New Drug Application (NDA), potentially exposing shareholders to significant financial losses.

The lawsuit targets investors who purchased Corcept securities during a specific window—between October 31, 2024 and December 30, 2025—a period when the company's stock price may have been artificially inflated by allegedly misleading disclosures. The filing represents a significant legal challenge for the pharmaceutical company and raises questions about its clinical development processes and regulatory compliance practices.

The Allegations and Clinical Background

At the heart of the class action complaint lies relacorilant, a selective glucocorticoid receptor modulator being developed primarily for the treatment of endogenous Cushing's syndrome. According to the lawsuit, Corcept made public statements suggesting robust clinical trial results and a clear path to FDA approval, while allegedly failing to disclose material information about regulatory agency concerns.

The key allegations include:

• Materially false statements regarding the adequacy and strength of clinical trial data supporting relacorilant's efficacy and safety profile
• Misleading representations about the likelihood and timeline of FDA approval for the drug's NDA
• Failure to disclose that the FDA had specifically raised concerns about the sufficiency of clinical evidence supporting the regulatory submission
• Omission of material facts that would have materially altered investor perception of the drug's commercialization prospects

The regulatory concerns allegedly raised by the FDA represent a critical juncture in the drug development process, as the agency's assessment of clinical evidence directly impacts whether a pharmaceutical company can proceed with commercialization. Such FDA concerns, when known to company management but not disclosed to investors, constitute the basis for securities fraud allegations under federal law.

Market Context and Competitive Landscape

Corcept Therapeutics operates in the specialized endocrinology pharmaceutical space, where competition centers on treatments for rare but serious hormonal disorders. Endogenous Cushing's syndrome, the primary indication for relacorilant, is a debilitating condition characterized by excess cortisol production, affecting a limited patient population but representing a significant unmet medical need.

The biopharmaceutical sector has faced heightened scrutiny regarding clinical trial transparency and regulatory disclosure practices. The FDA has increasingly emphasized the importance of robust clinical evidence, particularly for drugs targeting rare diseases where patient populations are smaller and trial designs become more critical. The agency's expressed concerns about relacorilant's clinical evidence suggest that Corcept may not have met the FDA's elevated evidentiary standards.

Investor confidence in pharmaceutical companies fundamentally depends on:

• Transparent reporting of clinical trial results and regulatory interactions
• Timely disclosure of FDA feedback that could impact approval prospects
• Honest characterization of regulatory timelines and likelihood of success
• Adequate internal controls to ensure compliance with securities laws

For smaller specialized pharmaceutical companies like Corcept, with limited product portfolios, the success or failure of a single drug candidate carries outsized importance. Relacorilant appears to represent a significant component of the company's value proposition, making accurate disclosure about its regulatory status essential for investor decision-making.

Investor Implications and Class Action Process

The filing of this class action lawsuit carries substantial implications for Corcept shareholders and the broader biopharmaceutical investment community:

For Affected Shareholders: Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 may be eligible to recover damages if the lawsuit succeeds. The damages calculation would typically be based on the difference between the artificially inflated price at which shares were purchased and the lower price following disclosure of the FDA concerns. Class action participation generally requires no out-of-pocket cost for individual investors, as lawyers work on a contingency basis.

For the Company: The lawsuit represents both immediate legal liability and reputational risk. Beyond potential financial settlements, successful securities fraud litigation can result in:

• Significant financial judgments against the company
• Increased regulatory scrutiny from the SEC and FDA
• Reputational damage affecting relationships with investors, collaborators, and regulators
• Increased litigation costs for defense and potential other shareholder actions
• Potential impact on future fundraising efforts or strategic partnerships

Regulatory and Industry Implications: This case underscores the critical importance of pharmaceutical companies maintaining rigorous disclosure practices regarding clinical and regulatory developments. The SEC and investor protection advocates increasingly focus on whether companies adequately inform investors about regulatory feedback that could materially affect commercialization prospects.

Pharmaceutical executives and boards must balance the competitive advantage of moving quickly through development cycles with the legal obligation to promptly disclose material negative regulatory feedback. The FDA's feedback about clinical evidence adequacy—if received before public disclosure—constitutes material nonpublic information that securities laws require be disclosed or could form the basis for fraud allegations.

Market Precedent: Securities litigation against pharmaceutical companies is not uncommon when clinical setbacks or regulatory disappointments occur unexpectedly from an investor perspective. However, successful cases typically require evidence that management knew of problems but made affirmative misstatements or selectively disclosed information. The allegation that Corcept specifically concealed FDA concerns about clinical evidence adequacy, if proven, would establish a strong basis for investor recovery.

Forward-Looking Considerations

As this litigation proceeds, several developments will merit close monitoring. First, the court must determine whether Corcept's public statements were sufficiently misleading and whether the company had adequate opportunity to disclose the FDA concerns. Second, the company's regulatory path forward with relacorilant remains unclear—whether the FDA will allow resubmission with additional clinical data, whether the company will pursue alternative indications, or whether the program may be abandoned entirely.

For investors currently holding Corcept shares or considering investment in the company, understanding the relacorilant situation becomes critical to valuation models. Any significant portion of company value attributed to this program should be heavily discounted pending regulatory resolution.

The class action lawsuit highlights a fundamental tension in pharmaceutical investing: the balance between management's desire to present optimistic development narratives and investors' need for complete, accurate information about regulatory interactions and clinical reality. Bronstein, Gewirtz & Grossman LLC's action on behalf of shareholders reflects growing investor protection efforts in this sector, where material information gaps can quickly translate into substantial financial losses.